327 related articles for article (PubMed ID: 33829482)
1. The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up.
Lebwohl M; Deodhar A; Griffiths CEM; Menter MA; Poddubnyy D; Bao W; Jehl V; Marfo K; Primatesta P; Shete A; Trivedi V; Mease PJ
Br J Dermatol; 2021 Nov; 185(5):935-944. PubMed ID: 33829482
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.
Deodhar A; Mease PJ; McInnes IB; Baraliakos X; Reich K; Blauvelt A; Leonardi C; Porter B; Das Gupta A; Widmer A; Pricop L; Fox T
Arthritis Res Ther; 2019 May; 21(1):111. PubMed ID: 31046809
[TBL] [Abstract][Full Text] [Related]
3. Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis.
Elewski BE; Baddley JW; Deodhar AA; Magrey M; Rich PA; Soriano ER; Soung J; Bao W; Keininger D; Marfo K; Patekar M; Sharma A; Shete A; Lebwohl MG
JAMA Dermatol; 2021 Jan; 157(1):43-51. PubMed ID: 33001147
[TBL] [Abstract][Full Text] [Related]
4. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials.
Schreiber S; Colombel JF; Feagan BG; Reich K; Deodhar AA; McInnes IB; Porter B; Das Gupta A; Pricop L; Fox T
Ann Rheum Dis; 2019 Apr; 78(4):473-479. PubMed ID: 30674475
[TBL] [Abstract][Full Text] [Related]
5. Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.
Gottlieb AB; Deodhar A; Mcinnes IB; Baraliakos X; Reich K; Schreiber S; Bao W; Marfo K; Richards HB; Pricop L; Shete A; Trivedi V; Keefe D; Papavassilis CC; Jagiello P; Papanastasiou P; Mease PJ; Lebwohl M
Acta Derm Venereol; 2022 Apr; 102():adv00698. PubMed ID: 35146532
[TBL] [Abstract][Full Text] [Related]
6. Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study.
Kiltz U; Sfikakis PP; Gaffney K; Sator PG; von Kiedrowski R; Bounas A; Gullick N; Conrad C; Rigopoulos D; Lespessailles E; Romanelli M; Ghislain PD; Brandt-Jürgens J; Rashkov R; Aassi M; Orsenigo R; Perella C; Pournara E; Gathmann S; Jagiello P; Veit J; Augustin M
Adv Ther; 2020 Jun; 37(6):2865-2883. PubMed ID: 32378070
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials.
Deodhar A; Blauvelt A; Lebwohl M; Feely M; Kronbergs A; Eberhart N; Zhu D; Inman E; Grace E; Holzkaemper T; Rahman P; Marzo-Ortega H; Papp KA; Merola JF; Gottlieb AB; Schwartzman S
Arthritis Res Ther; 2024 Feb; 26(1):49. PubMed ID: 38347650
[TBL] [Abstract][Full Text] [Related]
8. The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis.
van de Kerkhof PCM
Br J Dermatol; 2021 Nov; 185(5):879. PubMed ID: 34402525
[No Abstract] [Full Text] [Related]
9. Incidence of Uveitis in Secukinumab-treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies.
Deodhar AA; Miceli-Richard C; Baraliakos X; Marzo-Ortega H; Gladman DD; Blanco R; Das Gupta A; Martin R; Safi J; Porter B; Shete A; Rosenbaum JT
ACR Open Rheumatol; 2020 May; 2(5):294-299. PubMed ID: 32352653
[TBL] [Abstract][Full Text] [Related]
10. Persistence of secukinumab in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Conesa-Nicolás E; García-Lagunar MH; Núñez-Bracamonte S; García-Simón MS; Mira-Sirvent MC
Farm Hosp; 2020 Dec; 45(1):16-21. PubMed ID: 33443473
[TBL] [Abstract][Full Text] [Related]
11. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease.
Burmester GR; Panaccione R; Gordon KB; McIlraith MJ; Lacerda AP
Ann Rheum Dis; 2013 Apr; 72(4):517-24. PubMed ID: 22562972
[TBL] [Abstract][Full Text] [Related]
12. Secukinumab for children and adolescents with enthesitis-related arthritis and psoriatic arthritis:
Bagri NK; King H; Ramanan AV
Expert Rev Clin Immunol; 2024 May; 20(5):435-440. PubMed ID: 38186357
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease.
Reich K; Warren RB; Coates LC; Di Comite G
J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1161-1173. PubMed ID: 31785165
[TBL] [Abstract][Full Text] [Related]
14. Secukinumab as a potential trigger of inflammatory bowel disease in ankylosing spondylitis or psoriatic arthritis patients.
Onac IA; Clarke BD; Tacu C; Lloyd M; Hajela V; Batty T; Thoroughgood J; Smith S; Irvine H; Hill D; Baxter G; Horwood N; Mahendrakar S; Rajak R; Griffith S; Kiely PDW; Galloway J
Rheumatology (Oxford); 2021 Nov; 60(11):5233-5238. PubMed ID: 33677579
[TBL] [Abstract][Full Text] [Related]
15. Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis.
Deodhar A; Gladman DD; McInnes IB; Spindeldreher S; Martin R; Pricop L; Porter B; Safi J; Shete A; Bruin G
J Rheumatol; 2020 Apr; 47(4):539-547. PubMed ID: 31203228
[TBL] [Abstract][Full Text] [Related]
16. Treating to Target(s) With Interleukin-17 Inhibitors.
Lynde CW; Beecker J; Dutz J; Flanagan C; Guenther LC; Gulliver W; Papp K; Rahman P; Sholter D; Searles GE
J Cutan Med Surg; 2019; 23(2_suppl):3S-34S. PubMed ID: 30742778
[TBL] [Abstract][Full Text] [Related]
17. Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative.
Colombo GL; Di Matteo S; Martinotti C; Jugl SM; Gunda P; Naclerio M; Bruno GM
Clinicoecon Outcomes Res; 2018; 10():477-491. PubMed ID: 30214261
[TBL] [Abstract][Full Text] [Related]
18. Secukinumab for the treatment of psoriatic arthritis.
Baronaite Hansen R; Kavanaugh A
Expert Rev Clin Immunol; 2016 Oct; 12(10):1027-36. PubMed ID: 27550397
[TBL] [Abstract][Full Text] [Related]
19. Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications.
Gottlieb AB; Gordon K; Giannini EH; Mease P; Li J; Chon Y; Maddox J; Weng HH; Wajdula J; Lin SL; Baumgartner SW
J Drugs Dermatol; 2011 Mar; 10(3):289-300. PubMed ID: 21369647
[TBL] [Abstract][Full Text] [Related]
20. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.
Bonafede M; Joseph GJ; Princic N; Harrison DJ
J Med Econ; 2013 Sep; 16(9):1120-8. PubMed ID: 23808901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
